What is the Future Scope of Protein Expression Market amidst COVID-19?

Pune, India, 2020-Apr-10 — /EPR Network/ —

The ongoing COVID-19 pandemic—and the worldwide reaction to it—has compelled companies to radically rethink their strategies and the way they operate. We salute the industry experts helping companies survive and sustain in this pandemic.

At MarketsandMarkets™, analysts are undertaking continuous efforts to provide analysis of the COVID-19 impact on the Protein Expression Market. We are working diligently to help companies take rapid decisions by studying:

• The impact of COVID-19 on the Protein Expression Market, including growth/decline in product type/use cases due to the cascaded impact of COVID-19 on the extended ecosystem of the market
• The rapid shifts in the strategies of the Top 50 companies in the Protein Expression Market
• The shifting short-term priorities of the top 50 companies’ clients and their client’s clients

You can request an in-depth analysis detailing the impact of COVID-19 on the Protein Expression Market: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=180323924

According to the recent report  “Protein Expression Market by Type (E. Coli, Mammalian, Yeast, Pichia, Insect, Baculovirus, Cell-free), Products (Competent Cells, Reagents, Instruments, Services), Application (Therapeutic, Research, Industrial) & End User – Global Forecast to 2022″, is expected to reach USD 2,850.5 Million by 2022 from USD 1,654.0 Million in 2017, at a CAGR of 11.5% during the forecast period.

Browse in-depth TOC on “Protein Expression Market”

127 – Tables
38 – Figures
173 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180323924

By systems type, the prokaryotic expression systems segment is expected to dominate the market in 2017

On the basis of systems type, the protein expression market is segmented into prokaryotic expression systems; insect cell expression systems; mammalian cell expression systems; yeast expression systems; cell-free expression systems; and algal-based expression systems.

The prokaryotic expression systems segment has been sub-segmented into Escherichia coli (E. coli) systems and other systems. The E. coli systems segment accounted for the largest share of this market segment. This growth can be attributed to the increasing use of E. coli systems for the production of commercial proteins.

By product, the reagents segment is expected to hold the largest share of the market in 2017

The protein expression market is segmented into competent cells, expression vectors, instruments, reagents, and services on the basis of products. The reagents segment holds the largest share and also expected to grow at the highest growth rate during the forecast period. This positive growth trend is primarily attributed to increasing research activities and large-scale production of antibodies and vaccines that require kits and reagents.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=180323924

Asia offers lucrative growth opportunities

By region, the global protein expression market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While North America holds the largest share of the market in 2016, Asia is expected to grow at the highest CAGR during the forecast period. The presence of emerging economies like China and India; the large population and rising prevalence of chronic diseases in these countries; a growing demand of biologics; and the improving life sciences research infrastructure are the major factors driving the growth of this regional segment.

Key players operating in the protein expression market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson & Company (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Takara Bio Inc. (Japan), Lonza Group Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), GenScript Biotech Corporation (China), Lucigen Corporation (U.S.), Synthetic Genomics Inc. (U.S.), Promega Corporation (U.S.), New England Biolabs, Inc. (U.S.), Sengenics (Singapore.), ARTES Biotechnology GmbH (Germany), Addgene Inc. (U.S.) , LifeSensors Inc. (U.S.), Accelagen Inc. (U.S.), Geneva Biotech (Switzerland), Viva Biotech (China), Profacgen (U.S.), ProteoGenix (France), Peak Proteins Ltd. (U.K.), Domainex Ltd. (U.K.), and Jena Bioscience GmbH (Germany)